Citius Pharmaceuticals (NASDAQ:CTXR) Trading Down 5.1% – Time to Sell?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s share price fell 5.1% during trading on Wednesday . The company traded as low as $2.44 and last traded at $2.59. 139,545 shares changed hands during mid-day trading, an increase of 35% from the average session volume of 103,469 shares. The stock had previously closed at $2.73.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th. D. Boral Capital restated a “hold” rating on shares of Citius Pharmaceuticals in a research note on Friday, November 22nd.

Citius Pharmaceuticals Stock Performance

The company has a market cap of $18.80 million, a price-to-earnings ratio of -0.43 and a beta of 1.48. The stock’s fifty day moving average is $6.39 and its two-hundred day moving average is $12.60.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several large investors have recently bought and sold shares of CTXR. Point72 DIFC Ltd purchased a new stake in Citius Pharmaceuticals in the 2nd quarter valued at about $29,000. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals during the third quarter valued at approximately $47,000. Virtu Financial LLC purchased a new stake in shares of Citius Pharmaceuticals during the third quarter valued at approximately $50,000. Miller Investment Management LP lifted its holdings in Citius Pharmaceuticals by 99.3% during the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after acquiring an additional 49,640 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Citius Pharmaceuticals in the second quarter worth $69,000. 16.88% of the stock is currently owned by institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.